Skip to main content
×
×
Home

Evolution of HCV incidence in drug users in France

  • D. LUCIDARME (a1) (a2) (a3), C. DUBURQUE (a1) (a2) (a3), P. BULOIS (a1) (a2) (a3) and B. FILOCHE (a1) (a2) (a3)
Summary

Over the last 40 years, the dynamics of hepatitis C virus (HCV) infection in drug users has been affected by the illicit drug market, the health environment including the devastating impact of the HIV/AIDS epidemic which erupted in the 1980s, and the diffusion of substitution treatment beginning in 1995. The purpose of this literature review is to present the dynamics of HCV infection in drug users in France over the last 40 years. Two prevalence studies of HCV infection in the general population were conducted by the French Institute for Public Health Surveillance in 1994 and 2004 and were the touchstone data sources for this analysis. Hypotheses constructed from the findings of these two studies were examined in light of results reported by multicentre prevalence and incidence studies in drug-user populations. The incidence of HCV infection in drug users in France reached a peak in the late 1980s or early 1990s after a lengthy period of epidemic expansion. Implementation of a risk reduction policy enabled a very significant reduction in the incidence of HCV infection in drug users over the last 20 years, leading to incidence figures which are now 10–15% of the 1990 estimate.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Evolution of HCV incidence in drug users in France
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Evolution of HCV incidence in drug users in France
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Evolution of HCV incidence in drug users in France
      Available formats
      ×
Copyright
Corresponding author
*Author for correspondence: D. Lucidarme, M.D., Service de Pathologie Digestive, Centre Hospitalier Saint Philibert, 115 rue du Grand But, 59462 Lomme Cedex, France. (Email: lucidarme.damien@ghicl.net)
References
Hide All
1.Costes, JM. The prevalence of problem drug use in France: estimates for 2006 (http://www.ofdt.fr/ofdtdev/live/english-tab/engpubli/tends/tend69eng.html). Accessed 2009.
2.Crofts, N, et al. Minimising harm from hepatitis C virus needs better strategies. British Medical Journal 2000; 321: 899.
3.Kamili, S, et al. Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infection Control and Hospital Epidemiology 2007; 28: 519524.
4.Hagan, H, et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health 2001; 91: 4246.
5.Lucidarme, D, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiology and Infection 2004; 132: 699708.
6.De, P, et al. Risk of hepatitis C virus transmission through drug preparation equipment: a systematic and methodological review. Journal of Viral Hepatitis 2008; 15: 279292.
7.Tortu, S, et al. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Substance Use and Misuse 2004; 39: 211224.
8.Martinez, A, Talal, AH. Noninjection drug use: an under-appreciated risk factor for hepatitis C virus transmission. Liver International 2008; 28: 757760.
9.Micallef, JM, Kaldor, JM, Dore, GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. Journal of Viral Hepatitis 2006; 13: 3441.
10.Lai, ME, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343: 388390.
11.Bowden, S, et al. Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users. Journal of Viral Hepatitis 2005; 12: 322324.
12.Micallef, JM, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. Journal of Viral Hepatitis 2007; 14: 413418.
13.Van De Laar, TJ, et al. Frequent HCV reinfection and superinjection in a cohort of injecting drug users in Amsterdam. Journal of Hepatology 2009; 51: 667674.
14.Grebely, J, et al. Hepatitis C virus reinfection in injection drug users. Hepatology 2006; 44: 11391145.
15.Osburn, WO, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315324.
16.Six, C, Hamers, F, Brunet, JB. HIV, HCV and HBV infections among drug users attending care centres with housing accommodations 1993–1998. Bulletin Epidémiologique Hebdomadaire 1999; 32: 14.
17.Bello, PY, et al. Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies. European Journal of Clinical Microbiology and Infectious Diseases 1998; 17: 570572.
18.Jauffret-Roustide, M, et al. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infectious Diseases 2009; 9: 113.
19.Amin, J, et al. Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiology and Infection 2007; 135: 144150.
20.Lopez, D, Martineau, H, Palle, C. Mortality of individuals arrested for heroin, cocaine or crack use (http://www.ofdt.fr/BDD/publications/docs/eftadlk5.pdf). Accessed 2004.
21.Mathei, C, et al. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users. Journal of Viral Hepatitis 2006; 13: 560570.
22.Dubois, F, et al. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 1997; 25: 14901496.
23.Meffre, C, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. Journal of Medical Virology 2010; 82: 546555.
24.Valenciano, M, Emmanuelli, J, Lert, F. Unsafe injecting practices among attendees of syringe exchange programmes in France. Addiction 2001; 96: 597606.
25.Palle, C, Vaissade, L. The initial national results of the RECAP survey (http://www.ofdt.fr/ofdtdev/live/english-tab/engpubli/tends/tend54eng.html). Accessed 2007.
26.Downs, AM, et al. Reconstruction and prediction of the HIV/AIDS epidemic amoung adults in the European Union and in the low prevalence countries of central and eastern Europe. AIDS 1997; 11: 649662.
27.Deuffic, S, et al. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 15961601.
28.Di Nino, F, et al. Screening and treatment of hepatitis C by the microstructure medical network in Alsace, France, 2006–2007. Bulletin Epidémiologique Hebdomadaire 2009; 37: 48.
29.Lucidarme, D, et al. Prevalence of hepatitis C, B and D markers and histopathological aspects in a group of intravenous drug addicts. Gastroentérologie Clinique et Biologique 1994; 18: 964968.
30.Chossegros, P. Management of drug addiction in France (a short history). Gastroentérologie Clinique et Biologique 2007; 31: S4450.
31.Toufik, A. Distribution of intravenous injection in France (http://www.ofdt.fr/BDD/publications/docs/tend5gb.pdf). Accessed 1999.
32.Costes, JM. A prevalence estimate. In: Carpentier, C, Costes, JM, eds. Drogues et Toxicomanies: Indicateurs et Tendances, 1995, pp. 4445.
33.Toufik, A, Escots, S, Cadet-Tairou, A. Change in drugs use linked to the diffusion of substitution treatments. Illicit drug uses in France since 1999, from the TREND system. French Observatory for Drugs and Drug Addiction (OFDT), 2010.
34.OFDT.Drugs and drug use in France. Levels of use and recent trends 2007–2009. French Observatory for Drugs and Drug Addiction, 2010 Report (http://www.ofdt.fr/ofdtdev/live/publi/rapports/rap10/epfxacq1.html). Accessed 2010.
35.OFDT.Illicit drug use in France since 1999, from the TREND system. Costes JM (Dir.). French Observatory for Drugs and Drug Addiction, 2010, 191 pp.
36.Meffre, C, et al. Prevalence of hepatitis B and C in France in 2004. Institut de veille sanitaire, Saint-Maurice, March 2007, 114 pp.
37.Desenclos, JC, Costagliola, D, Commenges, D, et al. Prevalence of HIV infection in France. Bulletin Epidémiologique Hebdomadaire 2005; 11: 4144.
38.OFDT.Drugs and dependence: indicators and trends of the French Drug Abuse Observatory, 1999. French Observatory for Drugs and Drug Addiction.
39.Emmanuelli, J, Jauffret-Roustide, M, Barin, F. Epidemiology of HCV infection among drug users, France, 1993–2002. Bulletin Epidémiologique Hebdomadaire 2003; 16–17: 1315.
40.Jauffret-Roustide, M, et al. Estimate of HIV and HCV prevalence and patterns of drug users in France, InVS-ANRS Coquelicot study, 2004. Bulletin Epidémiologique Hebdomadaire 2006; 33: 244247.
41.Emmanuelli, J, Desenclos, JC. Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003. Addiction 2005; 100: 16901700.
42.Delarocque-Astagneau, E, et al. The hepatitis C surveillance system committee and the scientific committee for the national prevalence survey of hepatitis B and C markers. The impact of the prevention programme of hepatitis C over more than a decade: the French experience. Journal of Viral Hepatitis 2010; 17: 435443.
43.Cadet-Tairou, A, et al. Health status of drug users. Drugs and drug use in France. Levels of use and recent trends 2007–2009. Ninth Edition of the National Report of the TREND system. French Observatory for Drugs and Drug Addiction (OFDT), 2010.
44.Jauffret-Roustide, M, et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data-the ANRS-Coquelicot Study. Substance Use and Misuse 2006; 41: 16031621.
45.Van Den Berg, CH, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. European Journal of Epidemiology 2007; 22: 183193.
46.Bello, PY, Cadet-Tairou, A, Halfen, S. Health status of problem drug users. Drugs and drug use in France. Illicit drug uses in France since 1999 from the TREND system. French Observatory for Drugs and Drug Addiction (OFDT), 2010.
47.DREES.Health status of the population in France. 2007 Report (http://www.sante.gouv.fr/IMG/pdf/esp2007-obj-56.pdf). Accessed 2007.
48.Dubois-Arber, F, et al. Trends in drug consumption and risk of transmission of HIV and hepatitis C virus among injecting drug users in Switzerland, 1993–2006. Eurosurveillance 2008; 13: 18881.
49.Schmitt, C, Bertel, J, Jacob, C. Incidence of serological markers of hepatitis B and C viruses and HIV in a population of drug abusers hospitalized from 1990 to 1992. Annales de Médecine Interne 1994; 145: 712.
50.Aaron, S, et al. Intranasal transmission of hepatitis C virus: virological and clinical evidence. Clinical Infectious Diseases 2008; 47: 931934.
51.Lettmeier, B, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. Journal of Hepatology 2008; 49: 528536.
52.Bruggmann, P, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. Journal of Viral Hepatitis 2008; 15: 747752.
53.Chossegros, P, et al. A French prospective observational study of the treatment of chronic hepatitis C in drug abusers. Gastroentérologie Clinique et Biologique 2008; 32: 850857.
54.Moussalli, J, et al. Management of hepatitis C among drug user patients. Gastroentérologie Clinique et Biologique 2007; 31: 4S514S55.
55.Backmund, M, et al. Treatment of hepatitis C infection in drug users. Hepatology 2001; 34: 188193.
56.Sylvestre, DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug and Alcohol Dependence 2002; 67: 117123.
57.Dalgard, O, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. European Addiction Research 2002; 8: 4549.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: -
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed